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Abstract
Purpose High-dose pegylated interferon -2b (peginter-
feron  -2b) signiWcantly decreased disease recurrence in
patients with resected stage III melanoma in a clinical
study. We investigated the pharmacokinetics (PK) and
safety of high-dose peginterferon -2b in patients with
high-risk melanoma.
Methods For PK analysis, 32 patients received peginter-
feron  -2b 6 g/(kg week) subcutaneously for 8 weeks
(induction) then 3 g/(kg week) for 4 weeks (maintenance).
PK proWles were determined at weeks 1, 8, and 12. Expo-
sure–response relationships between peginterferon -2b
and absolute neutrophil count (ANC) and alanine amino-
transferase (ALT) level were also studied.
Results Peginterferon -2b was well-absorbed following
SC administration, with a median Tmax of 24 h. Mean
half-life estimates ranged from 43 to 51 h. The accumula-
tion factor was 1.69 after induction therapy. PK parame-
ters showed moderate interpatient variability. PK proWles
were described by a one-compartmental model with Wrst-
order absorption and Wrst-order elimination. Toxicity was
proWled and was acceptable; observed side eVects were
similar to those previously described. Dose reduction
produced proportional decreases in exposure and predict-
able eVects on ANC in an Imax model; however, a PK/
pharmacodynamic (PK/PD) relationship between pegin-
terferon -2b and ALT could not be established with high
precision.
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Conclusions Peginterferon  -2b was well-absorbed and
sustained exposure to peginterferon -2b was achieved with
the doses tested. These data conWrm and extend previous
PK observations of peginterferon -2b in melanoma and
solid tumors. Our PK/PD model of exposure and ANC
eVect provides useful information for prediction of pegin-
terferon -2b-related hematologic toxicity.
Keywords Peginterferon -2b · Melanoma · 
Adjuvant therapy · Pharmacokinetics · Pharmacodynamics
Introduction
The conjugation of polyethylene glycol (PEG) to therapeu-
tically useful proteins has been widely employed to reduce
clearance and increase systemic exposure while preserving
biologic activity [1]. The addition of a 12 kDa mono-meth-
oxy-PEG linker to interferon produces a predominantly
mono-pegylated prodrug molecule that retains the activity
of the parent interferon and has a prolonged half-life that
lends itself to weekly administration [2].
High-dose recombinant (native) interferon -2b is
widely used and is approved by the US Food and Drug
Administration as adjuvant therapy in patients with high-
risk resected melanoma, based on its eVect on disease-free
survival (DFS) and overall survival (OS) in the pivotal
Eastern Cooperative Oncology Group (ECOG) 1684 trial
[3]. Further trials established the eVect of interferon -2b on
DFS, although its eVects on OS are somewhat controver-
sial, with only modest improvements in OS versus observa-
tion [3–7]. High-dose interferon -2b regimens are
associated with high toxicity [8] and a cumbersome, three-
times-weekly maintenance dosing schedule. Additionally,
several studies have demonstrated that peginterferon -2b
is more eVective than nonpegylated interferon in treating
hepatitis [9–12] owing to the altered pharmacokinetic (PK)
proWle and resultant prolonged drug exposure [11–13].
Peginterferon -2b has also shown promise in the treatment
of various solid tumors [2, 13, 14]. Given this information,
investigators started studying high-dose peginterferon -2b
for treatment of melanoma in the late 1990s [2, 13, 15].
The recently reported European Organisation for
Research and Treatment of Cancer (EORTC) 18991 phase
III trial studied the eYcacy of peginterferon -2b in high-
risk melanoma. Improvement in recurrence-free survival
(RFS) was seen in patients with node-positive melanoma
treated for up to 5 years with high-dose peginterferon -2b
compared with observation alone [15]. Therefore, high-
dose peginterferon -2b [6 g/(kg week) for 8 weeks fol-
lowed by 3 g/(kg week) for up to 5 years] could become a
new option for the adjuvant treatment of stage III patients
with high-risk melanoma. The dose used in the EORTC
18991 trial was substantially higher than that generally
used for the treatment of hepatitis C [1.5 g/(kg week)];
6 g/(kg week) subcutaneous (SC) dosing is expected to
provide an exposure (area under the curve; AUC) similar to
high-dose native interferon -2b 180 MIU/week intrave-
nously, which is the weekly dose a patient with a body
surface area of 1.8 m2 would receive in the Wrst 4 weeks of
standard high-dose adjuvant therapy for melanoma
[20 MIU/(m2 day) Wve times weekly] [13]. A recent publi-
cation reported limited PK data from a small subset of
patients (7%) receiving peginterferon -2b during the main-
tenance phase in the 18991 study [16]. The results indicated
sustained exposure to peginterferon -2b during long-term
adjuvant treatment, with dose-related changes in serum
trough concentrations. Mean serum concentrations were
similar to those observed in patients with hepatitis C; high
inter-subject variability was observed, consistent with hep-
atitis C studies. However, PK analysis was not planned in
the 18991 study protocol and was assessed using serum
samples obtained during routine clinical visits 1–6 months
apart for exploratory analysis of prognostic factors; there-
fore multiple sequential samples were not available for all
patients, and blood sampling was not always well-timed
relative to administration of the weekly drug dose. These
factors have important implications for the trough level
estimates in the 18991 PK analysis.
To provide data on the actual exposure and PK parameter
estimates for patients treated with this high-dose sched-
ule of peginterferon -2b, we conducted a prospective, sin-
gle-arm, open-label trial in resected, high-risk, stages II and
III melanoma. Given that absolute neutrophil count (ANC)
reduction and alanine aminotransferase (ALT) elevations
are two of the most common and signiWcant dose-limiting
organ toxicities with interferon treatment, and possibly
peginterferon  -2b [17], we explored PK/pharmacody-
namic (PK/PD) models of ANC and ALT changes
following peginterferon -2b SC administration and
attempted to model the expected eVect of dose modiWcation
on bone marrow suppression and hepatic toxicity.
Methods
Trial design
This prospective, open-label, single-arm, phase II PK trial
was conducted at four sites worldwide. The primary goal was
to determine the PK proWle of peginterferon -2b when
administered at the EORTC 18991 trial dose and schedule in
patients with high-risk melanoma. The secondary objective
was to assess the safety of this regimen. Additionally, explor-
atory modeling of the PD relationship between peginterferon
-2b exposure and ANC and ALT was carried out.Cancer Chemother Pharmacol (2011) 67:657–666 659
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The trial was approved by the local institutional review
boards and registered at http://www.clinicaltrials.gov
(NCT00457418). The trial opened in February 2007 and
completed accrual in September 2007.
Patients
Eligible patients were ¸18 years old and had histologically
documented American Joint Committee on Cancer stage
IIB, IIC, IIIA, IIIB, or IIIC melanoma, an ECOG perfor-
mance status of 0 or 1, and adequate bone marrow, renal,
and hepatic function. Full lymphadenectomy had to be per-
formed within 90 days prior to starting therapy. Patients
with a history of treatment with any interferon, chemother-
apy, or immunotherapy, and those with melanoma that
could not be completely surgically resected were excluded,
as were those with preexisting autoimmune disease or psy-
chiatric conditions. This study was conducted in accor-
dance with Good Clinical Practice guidelines and signed
informed consent was obtained prior to treatment initiation.
Treatment
Patients received peginterferon -2b 6 g/kg SC once
weekly during an 8-week induction period, followed by a
maintenance dosage of 3 g/kg SC once weekly for the
remainder of the treatment period for a maximum of
5 years. The Wrst 12 weeks constituted the PK phase
(8 weeks of induction and 4 weeks of maintenance); the
remainder was the post-PK phase. Dose modiWcation
guidelines were provided to manage toxicities, allowing
patients to continue treatment while maintaining an ECOG
performance status score of 0 or 1, per the EORTC 18991
trial [15]. Treatment was withheld if hematologic toxicity
occurred: white blood cells <1 £ 109/L; ANC <0.5 £ 109/
L; platelets <50 £ 109/L. After recovery, treatment could
be restarted one dose level down; subsequent dose
escalations were not permitted after dose reduction for
hematologic toxicity (see online resource material—sup-
plementary methods).
Safety evaluation
The cutoV date for safety data presented here was May 2008.
Baseline evaluations included history, physical examination,
complete blood count with diVerential, lipid proWles, and
renal, hepatic, and thyroid function assessments (see online
resource material—supplementary methods).
Blood collection and analysis
Blood samples for PK analysis were collected predose and
at 24, 48, 96, and 168 h postdose during weeks 1, 8, and 12.
In addition, a predose sample was drawn at weeks 11 and
12 to determine trough levels (see online resource mate-
rial—supplementary methods).
Noncompartmental PK analysis
PK parameters for individual serum peginterferon -2b
concentration–time data were estimated using noncompart-
mental (NCA) methods (WinNonlin software, version 4,
Pharsight, Mountain View, CA). Samples with concentra-
tions below the limit of quantitation of the bioanalytical
assay were assigned a concentration of 0 pg/mL. The fol-
lowing parameters were calculated from the concentration–
time data using this NCA: area under the curve during the
dosing interval (AUCtau), maximal serum concentration
(Cmax), average concentration within dosing interval (Cavg),
minimum (trough) serum concentration (Cmin), observed
time to achieve maximal serum concentration (Tmax), mean
apparent clearance (CL/F), terminal half-life (t1/2), and
accumulation factor (R) [18]. For weeks 1–8 (induction) R
was deWned as the ratio of the AUC0–168h for week 8
divided by the AUC0–168h for week 1. At week 1, the single
dose CL/F was calculated using dose/AUC1. At weeks 8
and 12, CL/F was calculated as dose/AUC0–168h. CL/F was
not determined for those patients whose elimination t1/2
could not be accurately determined at week 1.
Compartmental PK analysis
A one-compartment model and a two-compartment model
were evaluated using WinNonlin software. A one-compart-
ment model with Wrst-order absorption and Wrst-order elim-
ination (no lag time) appropriately described the PK
proWles for peginterferon -2b following multiple SC dos-
ing (see online resource material—supplementary methods
and supplementary Table 1). Individual serum concentra-
tions at weeks 1, 8, and 12 and trough concentration at
weeks 10 and 11 were used to obtain the individual Wtted
PK parameters (data not shown). Once the parameter values
were determined, the predicted serum concentration–time
proWles were generated and compared with actual data
obtained to assess the usefulness of the PK model. The
initial PK parameter estimates were based on either
the relevant literature or the initial value calculated by the
WinNonlin software.
PD modeling strategy and PK/PD analysis
Blood samples were collected at baseline and approxi-
mately every week subsequently to determine ANC and
ALT levels. PK/PD models were developed in order to
characterize the time course of ANC or ALT response after
SC administration of peginterferon -2b, using WinNonlin660 Cancer Chemother Pharmacol (2011) 67:657–666
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software. For both ANC and ALT, model selection was
driven by the available PK and PD data and was based on:
(1) graphical goodness-of-Wt analysis, (2) estimated uncer-
tainty in parameter estimates as reported by %CV, (3)
Akaike information criteria (AIC), and (4) plausibility of
parameter estimates. Initial parameter estimates were based
on the relevant literature or initial values provided by the
WinNonlin software and their plausibility ascertained.
Since only two dose levels were speciWed by this study pro-
tocol (excluding dose reductions), we pooled data from all
32 patients in our study with those of a diVerent trial [2],
which used a wide dose range in patients with solid tumors,
to better describe the dose–response relationship. Previ-
ously published steady-state exposure values (AUCtau at
week 4) from 34 patients with solid tumors treated with
doses ranging from 0.75 to 7.5 g/(kg week) (3–12 patients
in each dose group) [2] were used, along with the corre-
sponding ANC data from the same patients [unpublished
data, provided by Schering-Plough (now Merck & Co.)]. In
this previously published study, blood samples were col-
lected predose (hour 0) and at 24, 48, 72, and 168 h post-
dose during weeks 1 and 4. Six of the 34 patients with solid
tumors were melanoma patients.
EVects of peginterferon -2b exposure on ANC
The exposure–response relationship between steady-state
exposure to peginterferon -2b (AUCtau) and changes in
ANC from baseline was assessed at week 8 [dose 6 g/
(kg week)] and week 12 [3 g/(kg week)]. The inhibitory
Imax model was used to describe the exposure–response
relationship of ANC change as % of baseline and peginter-
feron -2b AUCtau (see online resource material—supple-
mentary methods and supplementary Table 1).
Based on serum concentrations and ANC data obtained
from patients in this study, a fully integrated PK/PD model
was used to describe the eVect of peginterferon -2b on ANC
over time. The PK component was a one-compartment
model with Wrst-order absorption and Wrst-order elimination.
The PD component of the model is an indirect inhibition
response model driven by the PK proWles [19, 20].
EVects of peginterferon -2b exposure on ALT
Again, a fully integrated PK/PD model was used to
describe the eVect of peginterferon -2b on the time course
of ALT change. The PK and PD components for the model
were as described for ANC above.
Statistical analyses
The protocol-deWned target sample size was 12 subjects;
assuming an inter-subject coeYcient of variation of 40%,
this was deemed suYcient to deWne the PK parameters such
that the 90% CI would be within 24% of the mean. There-
fore, between 20 and 30 subjects were to be enrolled to
ensure that 12 subjects would receive the full scheduled
dose of peginterferon -2b for 12 weeks. Summary statis-
tics are provided for PK parameters by dose and week with
the mean and %CV for the serum concentration data at each
sampling time. Steady state was assessed using log-trans-
formed Cmin for weeks 10, 11, and 12 using an ANOVA
model extracting eVects due to week and patient. Ratio esti-
mates and corresponding 90% CI were provided for each
week versus the average of the subsequent weeks. ANC and
ALT data were summarized by week.
Results
Patient characteristics and treatment exposure
Thirty-two patients participated in this trial. Baseline
patient demographics are summarized in Table 1. Dose
intensity was calculated by dividing the total dose received
in each phase by the corresponding time period for each
individual subject. Median dose intensity was 5.8 g/
(kg week) during the induction phase (weeks 1–8), 3.0 g/
(kg week) during the PK maintenance phase (weeks 9–12),
and 2.9 g/(kg week) during the post-PK phase. Most
patients (84%) received 7–8 weeks of induction therapy.
The median duration of treatment was 8.0 weeks (range
5.0–8.4) for induction and 4.0 weeks (range 1.0–4.1) for the
PK maintenance phase.
A total of 30 patients participated in the post-PK phase
(two patients did not enter follow-up), of whom 15 (50%)
discontinued therapy: 5 (17%) each due to adverse events
(AEs), disease progression, and patient preference. By July
2008 (last database lock), 15 (50%) patients remained on
treatment at a median of 13 months after beginning therapy.
Safety
Safety analyses were performed on all 32 patients. The
observed side eVects of peginterferon -2b were similar to
those previously described [2,  13,  15]. All patients
reported  ¸1 treatment-emergent AEs (TEAEs) of any
grade; 22 (69%) reported grade 3 or 4 TEAEs. TEAEs
reported in ¸10% of patients are presented in Table 2.
The most commonly occurring AEs included fatigue,
fever, chills, headache, anorexia, and nausea. Decreases in
ANC (all grades) were observed in seven (22%) patients;
decreases of grades 3 and 4 were observed in three (9%)
patients.
Serious AEs were reported in six (19%) patients: lower
limb and wrist fracture (one patient); drug hypersensitivity,Cancer Chemother Pharmacol (2011) 67:657–666 661
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bronchitis, and dehydration (one patient); urticaria (one
patient); cholecystitis (one patient); and atrial Wbrillation
(two patients). All serious AEs were grade 3 with the
exception of one grade 2 atrial Wbrillation.
AEs leading to dose modiWcation were reported in 17
(53%) patients and included fatigue and increased ALT
level (four patients (13%) each). Decreases in ANC (all
grades) led to dose reduction in two (6%) patients. AEs
leading to treatment discontinuation were reported in seven
(22%) patients and included lower leg fracture, atrial Wbril-
lation, fatigue, supraventricular tachycardia, blurred vision,
staphylococcal infection, and hypertriglyceridemia (one
patient each). No treatment-related deaths were reported.
Pharmacokinetics
Of the 32 patients enrolled on the study, Wve (16%) patients
discontinued treatment during the initial 12 weeks (PK
phase): two (6%) due to AEs, one (3%) due to disease pro-
gression, and two (6%) due to noncompliance with proto-
col. Another seven (22%) had missed/reduced doses, or
missed one or more speciWed PK sampling points, during
the PK phase. Data from the remaining 20 patients who
received full doses and provided all blood samples in the
PK phase were used for the primary PK analyses, as per the
protocol (a minimum of 12 patients was required). Data
from all 32 patients were pooled with data from patients
with advanced solid tumors (n = 34) [2] to help construct
the PK/PD model.
Table 1 Baseline demographics and tumor stage
Characteristic n =3 2
Age (years)
Mean § SD 49 § 13
Median (range) 50 (20–77)
18–65 years, n (%) 29 (91)
¸65 years, n (%) 3 (9)
Weight (kg)
Mean § SD 84 § 21
Median (range) 82 (46–137)
Missing 1
Sex, n (%)
Female 10 (31)
Male 22 (69)
Race, n (%)
White 31 (97)
Black or African American 1 (3)
Tumor stage, n (%)
IIB 2 (6)
IIIA 5 (16)
IIIB 19 (59)
IIIC 6 (19)
Table 2 Treatment-emergent adverse events reported in ¸10% of
patients in the total study population (n =3 2 )
a Leukopenia occurred at a frequency of <10% but is included as a
treatment-emergent adverse event of interest
Treatment-emergent 
adverse events
All grades 
n (%)
Grade 3/4 
n (%)
Hematologic
Neutropenia 7 (22) 2/1 (9)
Leukopeniaa 3 (9) 3/0 (9)
Gastrointestinal
Anorexia 28 (88) 0
Constipation 4 (13) 0
Diarrhea 19 (59) 0
Nausea 22 (69) 0
Vomiting 6 (19) 0
Dehydration 4 (13) 1/0 (3)
Constitutional symptoms
Insomnia 9 (28) 0
Chills 26 (81) 0
Fatigue 29 (91) 3/0 (9)
InXuenza-like illness 6 (19) 0
Night sweats 4 (13) 0
Fever 27 (84) 0
Metabolic/laboratory
Alanine aminotransferase 9 (28) 4/0 (13)
Aspartate aminotransferase 6 (19) 2/0 (6)
Triglyceride elevations 22 (69) 3/4 (22)
Pain
Headache 23 (72) 0
Arthralgia 5 (16) 0
Back 7 (22) 0
Myalgia 18 (56) 0
Neurology
Dizziness 4 (13) 0
Anxiety 7 (22) 0
Somnolence 5 (16) 0
Depression 11 (34) 0
Psychiatric
Insomnia 9 (28) 0
Sexual/reproductive function
Erectile dysfunction 4 (13) 0
Pulmonary/upper respiratory
Cough 12 (38) 0
Dyspnea 7 (22) 0
Skin/dermatology
Injection site reaction 6 (19) 0
Pruritus 7 (22) 0
Rash 8 (25) 1/0 (3)662 Cancer Chemother Pharmacol (2011) 67:657–666
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Noncompartmental analysis
Arithmetic means and coeYcients of variation (%CV) of
the estimated PK parameters at weeks 1, 8, and 12 from the
noncompartmental PK analysis (n = 20) are summarized in
Table 3. Peginterferon -2b was well-absorbed following
SC administration, with a median Tmax of 24 h. Dose-
related decreases in Cmax,  Cavg,  Cmin, and AUCtau were
observed following a dose decrease from 6 to 3 g/
(kg week). After 8 weeks of dosing at 6 g/(kg week) in the
induction phase, the accumulation factor (R) was 1.69.
CL/F values demonstrated that the dosage change from
induction to the maintenance phase did not appreciably
aVect estimates of CL/F. Mean half-life estimates ranged
from 43 to 51 h. PK parameters showed moderate interpatient
variability with %CV at weeks 1 and 8 ranging from 38
to 56%; variability was slightly lower at week 12 (range
24–43%; Table 3). In general, this regimen produced sus-
tained exposure to peginterferon -2b at these dosages.
The arithmetic means of observed peginterferon -2b
concentrations over time are shown in Fig. 1. Although the
dose level changed from 6 to 3 g/(kg week) at week 9
(maintenance phase), mean trough levels remained similar
at weeks 10, 11, and 12. Mean predose (trough) serum con-
centrations (%CV) at weeks 10, 11, and 12 were 684
(30%), 526 (56%), and 626 (43%) pg/mL, respectively.
To estimate whether steady state had been reached by
weeks 10 and 11, ratios of the least square (LS) mean
trough concentrations were calculated. The LS means were
1.31 [90% conWdence interval (CI) 1.07–1.61] for week 10
versus the average of weeks 11 and 12 and 0.74 (90% CI
0.58–0.93) for week 11 versus week 12. Conventionally,
steady-state conditions are indicated by LS mean ratios
between 0.80 and 1.25 [21]. Therefore, steady state could
not be conclusively demonstrated.
At present, most patients diagnosed with stage III mela-
noma in the United States have disease in a single sentinel
node, which is referred to as N1 disease. In the EORTC
18991 trial, patients with N1 (N1a and N2a) disease
appeared to derive beneWt from adjuvant peginterferon -2b
therapy [15, 22]. Therefore, we also analyzed PK parame-
ters for the subset of patients with N1a melanoma (n =5 ) .
The results were consistent with those observed for all
patients, although the exposure was marginally higher at
week 8 (data not shown). As a result of the limited sample
size for patients with N1 disease, no statistical analyses
were conducted to compare the exposures in patients with
diVerent stages of disease.
One-compartmental PK analyses
The PK proWles for SC dosing can be described by a one-
compartmental PK model with Wrst-order absorption and
Table 3 Pharmacokinetic parameters of peginterferon -2b following once-weekly subcutaneous dosing (n =2 0 )
AUCtau, area under the concentration–time curve during the dosing interval (168 h); Cavg, average concentration within dosing interval; Cmax, max-
imal serum concentration; Cmin, minimum serum concentration; CL/F, apparent clearance; %CV, coeYcient of variation expressed as a percentage;
NA, not available; R, accumulation factor; t1/2, terminal half-life; Tmax, observed time to achieve Cmax
a Median (range)
b Accumulation factor R = AUCtau peginterferon -2b at week 8/AUCtau peginterferon -2b at week 1
c n = 14; CL/F cannot be reported for some patients because t1/2 cannot be determined accurately
d n = 19; no concentration data were available for one patient at week 12
Week Dose (g/kg) Arithmetic mean (%CV)
AUCtau (pg h/mL) Cmax (pg/mL) Cavg (pg/mL) Cmin (pg/mL) Tmax (h)a CL/F (l/h kg) t1/2 (h) Rb
1 6 324,000 (38) 3,980 (44) 1,930 (38) NA 24 (24–72) 0.0186 (50)c 46 (24)c NA
8 6 462,000 (35) 5,070 (51) 2,750 (35) 1,300 (56) 24 (24–72) 0.0152 (48) 51 (18)d 1.69 (64)
12 3 235,000 (24) 2,620 (33) 1,400 (24) 626 (43)d 24 (24–48) 0.0135 (25) 43 (19) NA
Fig. 1 Mean serum concentration–time proWles of peginterferon -2b
following once-weekly subcutaneous dosing in patients who com-
pleted 12 weeks of protocol-speciWed therapy without dose modiWca-
tion and who had complete pharmacokinetic samples for weeks 1, 8,
and 12 (n = 20). Experimentally observed values (open circles) as well
as the curve-Wtted line using a one-compartment pharmacokinetic
model are includedCancer Chemother Pharmacol (2011) 67:657–666 663
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Wrst-order elimination. The one-compartmental model-pre-
dicted concentration–time proWle is shown in Fig. 1. After
the peak is reached, serum levels follow a monoexponential
decay. The observed and model-predicted concentrations
correlate well, as demonstrated in Fig. 1. The model
describes the concentration–time proWles for the induction
treatment of 6 g/(kg week) from weeks 1–8 as well as the
initial portion of the maintenance phase at 3 g/(kg week)
(serum trough levels at weeks 9–11 and a full proWle at
week 12). The consistent Wt of this model across two dose
levels suggests linear kinetics of peginterferon -2b
through this dose range. Based on this model-predicted
concentration–time proWle, steady state was reached at
week 4 following 6 g/(kg week) SC dosing, and there was
no apparent additional accumulation during the initial
maintenance phase at 3 g/(kg week) (weeks 9–12; Fig. 1).
Therefore, this PK model provides a reasonable estimate
of exposure to peginterferon -2b for use in the integrated
PK/PD model.
PK/PD modeling
PK/PD models were developed in order to characterize the
association between exposure and ANC or ALT response
after SC administration of peginterferon -2b and to pro-
vide a model of the eVect of dose reduction on these param-
eters.
EVects of peginterferon -2b on ANC
Using pooled data from our patients with high-risk mela-
noma (n = 32) along with those from patients with
advanced solid tumors (n = 34) [2], a nonlinear PK/PD
relationship is seen between AUCtau and change in ANC
from baseline (Fig. 2). With increasing exposure to pegin-
terferon -2b, the ANC decreased relatively rapidly when
AUCtau <200,000 pg h/mL, but the relationship between
AUCtau and change in ANC from baseline appeared to
reach the maximum eVect at exposure (AUCtau)
400,000 pg h/mL, with <10% decline of ANC between
200,000 and 600,000 pg h/mL.
The median ANC change (% baseline) over time after
weekly SC administration of peginterferon -2b demon-
strated a rapid onset of eVect within 1 week then a plateau
between weeks 2 and 8; when the dose changed to 3 g/
(kg week), a slow return towards baseline level followed
(Fig. 3a). The low number of patients at week 6 (n =4 )
and the interpatient variability account for the wide error
bars at this time point. Particularly, one patient had an
ANC increase of 38% from baseline due to ANC rebound
following treatment cessation at weeks 4 and 5 [at week
6 ANC was measured before dosing was resumed at
6 g/(kg week)].
The one-compartment PK model linked with an indirect
response PD model appears to reasonably capture the time
course of the ANC. We simulated the eVects of a reduction
in peginterferon -2b dose at weeks 9–12 on ANC. Dose
modiWcation to 3, 2, or 1 g/(kg week) resulted in an ANC
increase of 13, 22, and 38%, respectively. In the absence of
dose reduction, i.e., peginterferon -2b dose kept at 6.0 g/
(kg week), ANC levels will remain similar to those
between weeks 2 and 8 (33% of baseline value). The
observed AUC increases during the maintenance phase
(weeks 9–12) in this study were in line with model predic-
tions (Fig. 3a). Similar results were observed when PK/PD
modeling was carried out using data only from patients who
received full doses and provided all blood samples in the
PK phase. A more detailed description of the model,
together with goodness-of-Wt plots, is provided in the online
resource material (supplementary methods, supplementary
Table 1 and Fig. 1).
EVects of peginterferon -2b on ALT
The observed and predicted changes in median ALT
with time are shown in Fig. 3b. The ALT proWle demon-
strates a delayed onset with a peak and trough pattern,
with ALT levels gradually increasing over time and
reaching a maximum between weeks 5 and 8 in the range
of 2.5–3£ baseline level. When the dose changed to
3 g/(kg week) (week 9), ALT levels gradually decreased
to approximately 2£ baseline values between weeks 10
and 12.
As shown in Fig. 3b, the indirect stimulatory response
model could describe the average trend of ALT change
Fig. 2 Relationship between peginterferon -2b area under the con-
centration–time curve during the dosing interval (AUCtau) and absolute
neutrophil count (ANC) changes as a percentage of baseline in patients
with melanoma (n = 32) and solid tumors (n = 34) receiving various
doses of peginterferon -2b (3–12 patients in each dose group)664 Cancer Chemother Pharmacol (2011) 67:657–666
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following SC administration of peginterferon -2b, but the
Wt was not as good as the ANC model. The individual ALT
levels were highly variable; a notably large standard error
was observed at week 4. Therefore, this model should be
treated with caution. Further details are provided in the
online resource material (supplementary methods and sup-
plementary Table 1). Similar results were observed when
PK/PD modeling was carried out using data only from
patients who received full doses and provided all blood
samples in the PK phase.
Discussion
Peginterferon -2b is assuming a role in melanoma therapy
based on the recent pivotal EORTC 18991 trial showing its
eYcacy in resected stage III melanoma [15]. The dose used in
the EORTC 18991 trial, 6 g/(kg week) for 8 weeks followed
by 3 g/(kg week) for up to 5 years, is much higher than that
used for hepatitis C [1.5 g/(kg week)]. Prior to the current
study being initiated, there were only limited data on systemic
exposure to high-dose peginterferon -2b, and no data were
available for melanoma patients receiving adjuvant therapy.
We show that peginterferon -2b was well-absorbed fol-
lowing SC administration. Some accumulation occurred
following 8 weeks of treatment at 6 g/(kg week). The
AUCtau for the 6 g/(kg week) dose in this study was com-
parable with that observed in a small phase I/II trial [2] in
patients with advanced solid tumors, although the AUCtau
for 3 g/(kg week) was lower in our study [2]. As expected,
the CL/F of peginterferon -2b was greatly reduced com-
pared with the clearance of native interferon -2b (231 mL/
h kg) [23]. Therefore, peginterferon -2b has an approxi-
mately 10-fold longer t1/2 as compared with native inter-
feron -2b (43–51 vs. 4 h, respectively). The CL/F and t1/2
in patients with melanoma were similar to those reported in
patients with hepatitis C (22 mL/h kg and 27–39 h, respec-
tively). The Cmax observed here was 3,980–5,070 pg/mL at
the 6 g/(kg week) dose and 2,620 pg/mL at the 3 g/
(kg week) dose (measured at 24 h). In a hepatitis C study,
Cmax varied between 15 and 44 h postdose [23]. Hence, the
Cmax in the current study could be potentially underesti-
mated for some patients since we collected the Wrst post-
dose PK sample at 24 h. The Cavg observed in the current
study for the 3 g/(kg week) dose (1,400 pg/mL) was com-
parable to the mean serum concentration observed in the
limited PK analysis of the 18991 study (1,434 pg/mL).
There is a diVerence in mean trough estimate at the 3 g/
(kg week) dose level between the 18991 PK study
(1,069 pg/mL) and the present study (626 pg/mL). This
may be because the timing of sampling to assess trough
levels in the 18991 PK study was not as rigorous as in our
study, and the 18991 analysis may have included post-dose
samples, potentially leading to an overestimation of mean
trough concentration [16]. In addition, PK sampling took
place over a much longer time period for the 18991 PK
analysis compared with the present study (up to 5 years vs.
12 weeks, respectively).
The comparison of pegylated and native interferon -2b
doses used in clinical trials is complicated by the diVering
measurement methods and units, schedules, and the speciWc
activities. Data in patients with hepatitis C show that
0.25 g/(kg week) peginterferon -2b results in a similar
anti-viral eVect as 9 MIU/week (3 MIU three times
weekly) native interferon -2b. Extrapolating from this
Fig. 3 Observed and predicted values of percentage changes from
baseline in a median absolute neutrophil count (ANC) and b median
alanine aminotransferase (ALT) levels. Simulation of percentage
changes from baseline in median ANC/ALT with induction dose at
6 g/(kg week) from weeks 1 to 8, and dose modiWcation of peginter-
feron -2b to 3, 2, 1, or 0 g/(kg week) during weeks 9–12Cancer Chemother Pharmacol (2011) 67:657–666 665
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data, 6.0 g/(kg week) may achieve exposure comparable
with that of interferon -2b at 20 MIU/m2/day intravenous
infusion Wve times weekly (180 MIU/week). The observed
AUCtau in patients with melanoma conWrmed the extrapola-
tion. We observed that SC dosing of 6 g/(kg week) for
8 weeks followed by 3 g/(kg week) was well tolerated
with toxicity similar to that observed in the EORTC 18991
trial; based on our experience with high-dose native inter-
feron -2b in patients with melanoma, it appeared to us that
our patients had lower incidence of fever and chills, but
more skin rashes and hypertriglyceridemia. The data sug-
gest that high-dose peginterferon -2b has a better overall
tolerability proWle compared with high-dose native inter-
feron -2b. In phase I/II studies, peginterferon -2b has also
been shown to be well tolerated and clinically active in
chronic myelogenous leukemia and renal cell cancer [13].
We developed PK/PD models and performed simulations
in order to visualize the eVect of peginterferon -2b exposure
on ANC and ALT levels, as these are clinically relevant
interferon toxicities. We modeled the relationship between
peginterferon  -2b AUCtau and the observed reduction in
ANC using data from our study as well as data from a prior
study in patients with advanced solid tumors [2]. This analy-
sis shows a steep dose response followed by a plateau around
AUC 400,000 pg h/mL. The PK/PD model predicts that the
ANC nadir is reached approximately 2 weeks after treatment
initiation. The trough peginterferon -2b concentration (Cmin)
closely mirrors the ANC nadir (Fig. 3a). A similar relation-
ship between peginterferon -2b dose and ANC changes
after 4 weeks of dosing was reported in patients with hepati-
tis C [23]. Future studies with more intensive PD and PK
sampling will assist in conWrming that the wave-like Xuctua-
tion in ANC levels shown in Fig. 3a occur in clinical prac-
tice, as predicted by the PK/PD model.
Since clinicians may be interested in peginterferon -2b
dose reductions for excessive neutropenia, we also simu-
lated the eVect of dose reduction on the ANC. If peginter-
feron -2b dose is reduced from 6 g/(kg week) to 0, the
ANC trends upward rapidly. While stepwise dose reduc-
tions (3–2–1 g/kg) were prescribed in the EORTC 18991
trial, the Imax model used here suggests that treatment
should be interrupted and resumed at a much lower dose
(50 or 33% of starting dose) upon resolution of neutrope-
nia, if grade 3 or 4 neutropenia is observed. Clearly, future
trials should examine this clinically relevant issue.
Progressive transaminase elevations (reversible upon
discontinuation of the drug) are a major factor in the ability
of patients with melanoma to tolerate the full prescribed
dose of peginterferon -2b; ALT elevation is an important
PD surrogate of high-dose interferon eVect on the liver [3–
5, 15]. Although the number of patients with grade 3 ALT
elevations in the current study is low (four patients; 13%),
the frequency is consistent with the EORTC 18991 trial
data (10% grade 3 liver function test AEs) [15]. There were
no grade 4 ALT elevations in our study. We explored this
relationship using a fully integrated PK/PD model. Our
model predictions for ALT did not appear to Wt our observed
data as well as for ANC, so further evaluation of this aspect
of peginterferon administration is also clearly warranted.
In this study, the PK proWle of high-dose peginterferon
-2b in patients with resected high-risk melanoma is
described. The tolerability and safety of this dose and
schedule appears to be broadly similar to that seen in previ-
ous studies. The PK/PD model of the eVects of peginter-
feron -2b exposure on ANC provides a useful framework.
In contrast to high-dose interferon -2b, hematologic and/or
hepatic toxicity was less common and primarily grade 1 or
2 in severity with peginterferon -2b 6 g/(kg week)
(induction) and 3 g/(kg week) (maintenance). Based on
the safety proWle and PK data, combined with greater dos-
ing convenience, peginterferon -2b may potentially
improve compliance and eYcacy of adjuvant therapy for
patients with high-risk melanoma.
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